All News

A conversation with Kaitlin Bates, PharmD, ARHOME Quality Manager at Arkansas Blue Cross and Blue Shield, at PQA 2025.

Importing prescription drugs from Canada has been met with criticism, such as weakening the pharmaceutical supply chain and posing increased risks to patient safety.

Patients included in the study were aged 6 to 17 years with attention deficit/hyperactivity disorder (ADHD).

Pharmacists can substitute ustekinumab with the biosimilar at the pharmacy level, depending on their state laws.

Researchers investigate annual medication costs for children and determine which of them would qualify for medication therapy management based on CMS thresholds.

Researchers aim to understand how deprescribing interventions impacted changes in inappropriate medication use or total prescription drugs among older, community-dwelling adults.

A conversation with Michael Hegener, PharmD, BCACP, associate professor of Pharmacy at the University of Cincinnati, at PQA 2025.

V116 is noninferior to 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all 12 common serotypes and superior to 9 unique serotypes.

President of the National Foundation for Infectious Diseases, Jeff Goad, PharmD, MPH, discusses how pharmacists can help improve hepatitis A and B vaccine rates across the country.

Approximately 67% of adults in the US know that vaccines do not cause autism in children, declining significantly from 74% in 2021.

In part 2 of our video series with drug market experts Luke Turnock, PhD, and Jenny Markell, we explored social media advertisements for prescription drugs and how they may impact patients.

A conversation with Mitchell Barnett, PharmD, MS, professor of pharmaceutical sciences at Texas A&M University, at PQA 2025.

Researchers estimate the cost-effectiveness of PCV24 in the older adult population compared with the currently accepted pneumococcal vaccine schedules in the US.

Specialty pharmacies help support their continuity of care with practiced disaster response plans.

Researchers wanted to better understand prescribing patterns of pneumococcal vaccines for people living with HIV in a tertiary care hospital.

However, there is no association between cortisol and tau pathology.

Researchers conduct a scoping review to update and determine what the best available options are for treating patients with skin-picking disorder.

Pharmacies face mounting challenges amid increased competition, rising operational costs, and complex reimbursement models.

In children aged 5 to 17 with skin disorders, researchers explore the risk of developing psychosocial comorbidities, sleep disturbances, and common related symptoms.

Glucagon-like peptide-1 receptor agonists have been associated with improvements in quality of life (QOL), restrained eating, and emotional eating behavior.

Jeff Goad, PharmD, MPH, discusses hesitancy for hepatitis vaccines and the necessary advice pharmacists can utilize to help patients manage these misconceptions.

Novavax’s COVID-19 vaccine has been available in the US under emergency use authorization since July 2022.

Researchers conducted a clinical review detailing the intersection of dermatology and suicide, explaining why skin conditions lead to increased risk of poor mental health.

Investigators note that the long-term effects of attention deficit/hyperactivity disorder (ADHD) medication for children remain lacking.

The announcement comes shortly after the company announced it had filed its second chapter 11 bankruptcy in under 2 years.

Drug Market experts joined Drug Topics to discuss the rise in direct-to-consumer drug advertising and what it means for patients around the world.

Jeff Goad, PharmD, MPH, discusses hepatitis viruses and the current vaccination schedules available for patients to stay protected.

Dihydroergotamine (Brekiya) is an acute treatment to help relieve migraine attacks, and it can come in nasal sprays, injections, and intravenous infusions.

The investigators hope to pursue a human vaccine in order to improve upon the already existing vaccines.

Ronna Hauser, PharmD, Senior Vice President of Policy & Pharmacy Affairs at NCPA, provides insights into President Trump’s most recent executive order regarding manufacturer drug prices.